A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 26, 2023

Primary Completion Date

February 18, 2025

Study Completion Date

February 18, 2025

Conditions

Advanced Solid Tumor

Interventions

DRUG

ES009

ES009 is administered via intravenous infusion, once every 21 days.

Trial Locations (4)

Peninsula and South Eastern Oncology and Haematology Group, Frankston

St George Private Hospital, Kogarah

Scientia Clinical Research, Randwick

Sunshine Coast University Private Hospital, Sunshine Coast

All Listed Sponsors

lead

Elpiscience Biopharma Australia Pty. Ltd.

INDUSTRY

NCT06007482 - A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter